NICE first rejected Kadcyla back in 2014, saying its cost of around £91,000 per patient at full price was too high, and that a small discount was not enough for it to be considered cost effective.

Kadcyla was one of the most expensive drugs on the CDF, costing up to £65,000 per patients, and charity Breast Cancer Now took the unusual step of calling on Roche to lower its price.

Iksuda Therapeutics, a clinical stage and UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and ...

US FDA clears Iksuda Therapeutics’ IND application for IKS014: New Castle, England Wednesday, July 2, 2025, 15:00 Hrs [IST] Iksuda Therapeutics, a clinical stage and UK-based bi ...

FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical ...

NEWCASTLE, England, July 01, 2025--Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats ...

Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical activity across multiple tumour types Iksuda Therapeutics (Iksuda), the developer of class-leading ...

Get the latest Sonnet BioTherapeutics Holdings, Inc. (SONN) stock news and headlines to help you in your trading and investing decisions.

ACROBiosystems has developed a series of specialized proteases for the screening and validation of ADC linkers, focusing on ...

For example, Kadcyla (trastuzumab emtansine) obtained its European Medicine Agency (EMA) Market Authorization (MA) for the “Adjuvant treatment of adult patients with HER2-positive early breast cancer ...